Last reviewed · How we verify
quetiapine fumarate extended-release
At a glance
| Generic name | quetiapine fumarate extended-release |
|---|---|
| Also known as | SEROQUEL XR, Seroquel XR, FK949E, Seroquel XR (extended release), Seroquel SR |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (PHASE4)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
- Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression (PHASE4)
- Safety and Tolerability of Quetiapine in Multiple Sclerosis (PHASE1, PHASE2)
- Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes (PHASE4)
- Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- quetiapine fumarate extended-release CI brief — competitive landscape report
- quetiapine fumarate extended-release updates RSS · CI watch RSS
- AstraZeneca portfolio CI